Skip to main content

Neumann Mark's Form 4 filing

Intra-Cellular Therapies, Inc. (ITCI) · filed Nov 8, 2023

Accession no.
0001209191-23-054726
Filed
Nov 8, 2023
Trade date
Nov 6, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.36M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Neumann MarkCIK 0001756211Officer (EVP, Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 6, 2023Common StockMOption exerciseAcquired+26,754$23.94+$640,490.7672,093Direct
Nov 6, 2023Common StockSSaleDisposed−26,754$55.98−$1,497,688.9245,339Direct
Nov 6, 2023Common StockSSaleDisposed−15,639$55.02−$860,457.7829,700Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 6, 2023Common StockMOption exerciseDisposed−26,754$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)